Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.30 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3695186 | 0.84 | GABRA1 (0.34) | GABRA1GABRB2 | |
| Ammonia Solution, Strong SCHEMBL30386281 | 0.84 | GABRA1 (0.38) | GABRA1GABRB2MGLLHTTPSIP1 | |
| SCHEMBL3752108 | 0.82 | LIPG (0.44) | HTTMAPT | |
| SCHEMBL27530315 | 0.82 | GABRA1 (0.39) | GABRA1GABRB2MGLLHTTNPEPPS | |
| SCHEMBL17728688 | 0.77 | GABRA1 (0.35) | GABRA1GABRB2MGLLHTTNPEPPS | |
| O-Tolylamine SCHEMBL578081 | 0.77 | ACHE (0.38) | HTT | |
| SCHEMBL5703339 | 0.76 | GABRA1 (0.32) | GABRA1GABRB2MGLLHTT | |
| SCHEMBL6065924 | 0.75 | MAPT (0.32) | GABRA1GABRB2MGLLMAPTNPSR1 | |
| SCHEMBL8965995 | 0.75 | TYR (0.31) | — | |
| SCHEMBL5600458 | 0.74 | GABRA1 (0.38) | GABRA1GABRB2KAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760814-B2 | 1,5 diazabicyclooctane ligand systems and methods therewith | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2023-09-19 | — | — | US | claimed |
| US-20210032449-A1 | Polyethylene Copolymer and Method for Preparing Same | LG CHEM, LTD. (KR) | 2021-02-04 | — | — | US | disclosed |
| EP-1730203-A1 | CATALYST COMPOSITION AND USE THEREOF | ExxonMobil Chemical Patents, Inc., A Corporation of the State of Delaware (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095469-A1 | CATALYST COMPOSITION AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760814-B2 | 1,5 diazabicyclooctane ligand systems and methods therewith | ODC1, DDT, OXGR1 | GABRA1 2978/4885GABRB2 2861/4885MGLL 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.